NCT00082784 - Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

October 31, 2012

Study Completion Date

September 30, 2014

Conditions

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory Plasma Cell MyelomaSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

Bortezomib

Given IV

DRUG

Alvocidib Hydrochloride

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (5)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

University of Pittsburgh, Pittsburgh

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

29425

Medical University of South Carolina, Charleston

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH